Clinical trial
ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent…
NCT00439192 · elbion AG, Industry · Terminated
Key facts
| NCT number | NCT00439192 |
|---|---|
| Title | ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB) |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel Group, Phase II, Forced Dose Titration Study to Investigate the Efficacy and Safety of 400mg and 600mg ELB245 Given Once Daily for 12 Weeks (8 + 4 Weeks) Versus Placebo and Versus 4mg Tolterodine Given Once Daily in Patients With Incontinent… |
| Lead sponsor | elbion AG, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Overactive Bladder, Urinary Incontinence |
| Intervention type | Drug |
| Interventions | ELB245, Tolterodine |
| Enrollment | 275 |
| Start date | Feb 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Feb 23, 2007 |
| Last update posted | Aug 8, 2007 |
| Countries | Germany, Poland, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: